Cargando…

Prognostic impact of (18)F-FDG PET/CT in pathologic stage II invasive ductal carcinoma of the breast: re-illuminating the value of PET/CT in intermediate-risk breast cancer

BACKGROUND: The aim of this study is to investigate the impact of (18)F-FDG PET/CT on prognosis of stage II invasive ductal carcinoma (IDC) of the breast primarily treated with surgery. METHODS: The clinical records of 297 consecutive IDC with preoperative PET/CT and pathologically staged II in surg...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Hye Lim, Lee, Sea-Won, Hong, Ji Hyung, Lee, Jieun, Lee, Ahwon, Kwon, Soo Jin, Park, Sonya Youngju, Yoo, Ie Ryung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811771/
https://www.ncbi.nlm.nih.gov/pubmed/36600314
http://dx.doi.org/10.1186/s40644-022-00519-6
_version_ 1784863595829395456
author Park, Hye Lim
Lee, Sea-Won
Hong, Ji Hyung
Lee, Jieun
Lee, Ahwon
Kwon, Soo Jin
Park, Sonya Youngju
Yoo, Ie Ryung
author_facet Park, Hye Lim
Lee, Sea-Won
Hong, Ji Hyung
Lee, Jieun
Lee, Ahwon
Kwon, Soo Jin
Park, Sonya Youngju
Yoo, Ie Ryung
author_sort Park, Hye Lim
collection PubMed
description BACKGROUND: The aim of this study is to investigate the impact of (18)F-FDG PET/CT on prognosis of stage II invasive ductal carcinoma (IDC) of the breast primarily treated with surgery. METHODS: The clinical records of 297 consecutive IDC with preoperative PET/CT and pathologically staged II in surgery from 2013 to 2017 were retrospectively reviewed. The maximum standardized uptake value (SUVmax), peak standardized uptake value (SUVpeak), tumor-to-liver ratio (TLR), and metabolic tumor volume (MTV) were measured. Association of clinicopathologic factors (age, T stage, N stage, AJCC pathologic stage of IIA or IIB, pathologic prognostic stage, grade, hormonal receptor status, HER2 status, Ki-67, and adjuvant therapy) and PET parameters with DFS was assessed using the Cox proportional hazards model. RESULTS: There were 35 recurrences and 10 deaths at a median follow-up of 49 months (range 0.8 ~ 87.3). All PET parameters were significantly associated with DFS in univariate analysis but in multivariate analysis, SUVpeak was the only factor significantly associated with DFS (hazard ratio 2.58, 95% confidence interval 1.29–5.15, P = 0.007). In cohorts with higher values of SUVpeak or TLR, patients who received adjuvant chemotherapy had significantly superior DFS. CONCLUSION: Metabolic parameters derived from preoperative PET/CT was significantly associated with recurrence in stage II IDC primarily treated with surgery. PET/CT can be a powerful prognostic tool in conjunction with novel staging systems and current biomarkers for patients undergoing contemporary therapy. Our results urge to reconsider the currently underestimated value of PET/CT confined to diagnostic aspect and to newly recognize its prognostic impact in these intermediate-risk breast cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40644-022-00519-6.
format Online
Article
Text
id pubmed-9811771
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98117712023-01-05 Prognostic impact of (18)F-FDG PET/CT in pathologic stage II invasive ductal carcinoma of the breast: re-illuminating the value of PET/CT in intermediate-risk breast cancer Park, Hye Lim Lee, Sea-Won Hong, Ji Hyung Lee, Jieun Lee, Ahwon Kwon, Soo Jin Park, Sonya Youngju Yoo, Ie Ryung Cancer Imaging Research Article BACKGROUND: The aim of this study is to investigate the impact of (18)F-FDG PET/CT on prognosis of stage II invasive ductal carcinoma (IDC) of the breast primarily treated with surgery. METHODS: The clinical records of 297 consecutive IDC with preoperative PET/CT and pathologically staged II in surgery from 2013 to 2017 were retrospectively reviewed. The maximum standardized uptake value (SUVmax), peak standardized uptake value (SUVpeak), tumor-to-liver ratio (TLR), and metabolic tumor volume (MTV) were measured. Association of clinicopathologic factors (age, T stage, N stage, AJCC pathologic stage of IIA or IIB, pathologic prognostic stage, grade, hormonal receptor status, HER2 status, Ki-67, and adjuvant therapy) and PET parameters with DFS was assessed using the Cox proportional hazards model. RESULTS: There were 35 recurrences and 10 deaths at a median follow-up of 49 months (range 0.8 ~ 87.3). All PET parameters were significantly associated with DFS in univariate analysis but in multivariate analysis, SUVpeak was the only factor significantly associated with DFS (hazard ratio 2.58, 95% confidence interval 1.29–5.15, P = 0.007). In cohorts with higher values of SUVpeak or TLR, patients who received adjuvant chemotherapy had significantly superior DFS. CONCLUSION: Metabolic parameters derived from preoperative PET/CT was significantly associated with recurrence in stage II IDC primarily treated with surgery. PET/CT can be a powerful prognostic tool in conjunction with novel staging systems and current biomarkers for patients undergoing contemporary therapy. Our results urge to reconsider the currently underestimated value of PET/CT confined to diagnostic aspect and to newly recognize its prognostic impact in these intermediate-risk breast cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40644-022-00519-6. BioMed Central 2023-01-04 /pmc/articles/PMC9811771/ /pubmed/36600314 http://dx.doi.org/10.1186/s40644-022-00519-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Park, Hye Lim
Lee, Sea-Won
Hong, Ji Hyung
Lee, Jieun
Lee, Ahwon
Kwon, Soo Jin
Park, Sonya Youngju
Yoo, Ie Ryung
Prognostic impact of (18)F-FDG PET/CT in pathologic stage II invasive ductal carcinoma of the breast: re-illuminating the value of PET/CT in intermediate-risk breast cancer
title Prognostic impact of (18)F-FDG PET/CT in pathologic stage II invasive ductal carcinoma of the breast: re-illuminating the value of PET/CT in intermediate-risk breast cancer
title_full Prognostic impact of (18)F-FDG PET/CT in pathologic stage II invasive ductal carcinoma of the breast: re-illuminating the value of PET/CT in intermediate-risk breast cancer
title_fullStr Prognostic impact of (18)F-FDG PET/CT in pathologic stage II invasive ductal carcinoma of the breast: re-illuminating the value of PET/CT in intermediate-risk breast cancer
title_full_unstemmed Prognostic impact of (18)F-FDG PET/CT in pathologic stage II invasive ductal carcinoma of the breast: re-illuminating the value of PET/CT in intermediate-risk breast cancer
title_short Prognostic impact of (18)F-FDG PET/CT in pathologic stage II invasive ductal carcinoma of the breast: re-illuminating the value of PET/CT in intermediate-risk breast cancer
title_sort prognostic impact of (18)f-fdg pet/ct in pathologic stage ii invasive ductal carcinoma of the breast: re-illuminating the value of pet/ct in intermediate-risk breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811771/
https://www.ncbi.nlm.nih.gov/pubmed/36600314
http://dx.doi.org/10.1186/s40644-022-00519-6
work_keys_str_mv AT parkhyelim prognosticimpactof18ffdgpetctinpathologicstageiiinvasiveductalcarcinomaofthebreastreilluminatingthevalueofpetctinintermediateriskbreastcancer
AT leeseawon prognosticimpactof18ffdgpetctinpathologicstageiiinvasiveductalcarcinomaofthebreastreilluminatingthevalueofpetctinintermediateriskbreastcancer
AT hongjihyung prognosticimpactof18ffdgpetctinpathologicstageiiinvasiveductalcarcinomaofthebreastreilluminatingthevalueofpetctinintermediateriskbreastcancer
AT leejieun prognosticimpactof18ffdgpetctinpathologicstageiiinvasiveductalcarcinomaofthebreastreilluminatingthevalueofpetctinintermediateriskbreastcancer
AT leeahwon prognosticimpactof18ffdgpetctinpathologicstageiiinvasiveductalcarcinomaofthebreastreilluminatingthevalueofpetctinintermediateriskbreastcancer
AT kwonsoojin prognosticimpactof18ffdgpetctinpathologicstageiiinvasiveductalcarcinomaofthebreastreilluminatingthevalueofpetctinintermediateriskbreastcancer
AT parksonyayoungju prognosticimpactof18ffdgpetctinpathologicstageiiinvasiveductalcarcinomaofthebreastreilluminatingthevalueofpetctinintermediateriskbreastcancer
AT yooieryung prognosticimpactof18ffdgpetctinpathologicstageiiinvasiveductalcarcinomaofthebreastreilluminatingthevalueofpetctinintermediateriskbreastcancer